From next year, a large number of drugs will stop Medicare reimbursement!

"Pharmaceutical Network Industry Dynamics" October 10, Qinghai Health Insurance Bureau issued "on the issuance of Qinghai Province to supplement the drug digestion directory notice", decided to Qinghai Province to add 227 drugs out of health insurance.
According to the transfer arrangement, in 2020, a total of 129 varieties of drugs not used by the state-focused drug control and the drug procurement platform in Qinghai Province in the previous year will be transferred, and medical insurance and work injury insurance will be discontinued from January 1, 2021.
2022, the remaining 98 varieties will be transferred, and from January 1, 2023 to stop medical insurance, work injury insurance payments.
According to Qinghai Province's supplemental drug digestion catalogue, from next year, drugs that will not be reimbursed will include ammonia jaundika, compound ibuprofen, butamine carnamycin, BrinzoAnsemalor, dopamine glucose, etc.
the transfer of local medical insurance continues, in addition to Qinghai, according to the author incomplete statistics, from January 1 next year, Shaanxi, Chongqing, Beijing and other places have a number of drugs to stop medical insurance reimbursement.
Recently, Shaanxi Medical Insurance Bureau issued a notice, clearly in accordance with the relevant requirements of the State Health Insurance Administration, and gradually digest the original provincial drug catalogue in accordance with the provisions of the addition of Class B drugs, after expert demonstration and publicity, decided to transfer some drugs out of Shaanxi Province health insurance payment scope.
, from January 1, 2021, 63 kinds of drugs, such as aluminum hydroxide gel, will be transferred out of shaanxi Province's basic medical insurance, work injury insurance and health insurance payment range.
will also guide the designated medical institutions to notify the timely replacement of therapeutic drugs, to ensure the smooth implementation as scheduled.
Chongqing Municipal Health Insurance Bureau on June 8 issued "on the gradual digestion of chongqing city to supplement the list of medical insurance Class B drugs", clearly the first year of digestion of drugs, from January 1, 2021 to stop medical insurance reimbursement.
drugs that are no longer reimbursed include drugs with approval number "Drug Code B", medicines that have been included in the medical insurance catalogue but the manufacturer has not applied for medical insurance reimbursement, and medicines that do not have purchasing data at the Drug Exchange in 2019.
And in addition to the January 1, 2021 this point in time, so far, including Gansu and other 20 places have landed to implement the local supplement directory transfer policy, of which Yunnan, Hunan, Jilin, Tianjin, Hebei, Anhui, Tibet and other places have clearly the first batch of additional varieties of local health insurance, a large number of varieties are determined to be transferred out of the local health insurance directory on July 1, 2020.
Beijing has made it clear that from October 1 this year, 224 non-national medical insurance drug catalog varieties, such as benzodiaphenicol, will be transferred from the city's list of medical insurance drugs.
224 medicines, there are 136 Western medicines and 88 Chinese medicines.
Among them, there are common drugs, such as the western medicine has diabetes drug benzodiazepone, halomycin for the treatment of skin diseases, antibiotic-type drug Klinmycin, anti-heat analgesic drug ibuprofen and anti-snake serum injection preparations, etc. ;
that the main reason for the drug transfer is to implement the "three years to gradually digest the local medical insurance catalog of non-national medical insurance drug varieties" this unified national requirements.
can see that as local policies move forward, a large number of varieties will withdraw from health insurance in the future.
industry says the drugs that are generally transferred are mainly available that have been withdrawn or are used less clinically and have better alternatives.
therefore will not have too much impact on the clinical use of drugs by insured personnel.